In addition, the use of selective cyclooxygenase-2 inhibitors has a risk of ischemic heart disease [24], and medical doctors sometimes hesitate to use them in patients with a history of cardiovascular disease. This evidence concerns the gene PTGS2 and cardiovascular disorder.